How a single inversion of configuration leads to a reversal of the binding mode: proposal of a novel arrangement of CCK2 ligands in their receptor, and contribution to the development of peptidomimetic or non-peptide CCK2 ligands.

[1]  B. Maigret,et al.  Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode. , 2000, Journal of medicinal chemistry.

[2]  J. Crawley,et al.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.

[3]  B. Maigret,et al.  Evidence for a Direct Interaction between the Penultimate Aspartic Acid of Cholecystokinin and Histidine 207, Located in the Second Extracellular Loop of the Cholecystokinin B Receptor* , 1999, The Journal of Biological Chemistry.

[4]  B. Roques,et al.  CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology , 1999, Progress in Neurobiology.

[5]  B. Roques,et al.  SIDE-CHAIN-MODIFIED SULFONIC ANALOGUES OF ASPARTIC AND GLUTAMIC ACIDS : SYNTHESIS, PROTECTION, AND INCORPORATION INTO PEPTIDES , 1999 .

[6]  I. Léna,et al.  CCK in Anxiety and Cognitive Processes , 1998, Neuroscience & Biobehavioral Reviews.

[7]  S. Rose,et al.  Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. , 1998, Journal of medicinal chemistry.

[8]  R. Julien,et al.  Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. , 1997, Journal of medicinal chemistry.

[9]  B. Roques,et al.  Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. , 1997, Journal of medicinal chemistry.

[10]  M. D'Amato,et al.  CCKB/gastrin receptor antagonists as potential drugs for peptic ulcer therapy , 1997 .

[11]  B. Roques,et al.  Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. , 1997, Journal of medicinal chemistry.

[12]  D. Horwell.  Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. , 1996, Bioorganic & medicinal chemistry.

[13]  G. Woodruff,et al.  Characterization of novel peptoid agonists for the CCK-A receptor , 1996, Regulatory Peptides.

[14]  J. Hunter,et al.  The influence of guanyl nucleotide on agonist and antagonist affinity at guinea-pig CCK-B/gastrin receptors: Binding studies using [3H]PD140376 , 1996, Regulatory Peptides.

[15]  M. Pritchard,et al.  'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors. , 1996, Immunopharmacology.

[16]  B. Roques,et al.  Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives. , 1996, Bioorganic & medicinal chemistry.

[17]  M. K. James,et al.  Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". , 1996, Journal of medicinal chemistry.

[18]  Jacqueline N. Crawley,et al.  Biological actions of cholecystokinin , 1994, Peptides.

[19]  S. Guard,et al.  Rational design of high affinity tachykinin NK1 receptor antagonists. , 1994, Bioorganic & medicinal chemistry.

[20]  B. Roques,et al.  Conformational analysis of CCK‐B agonists using 1H‐nmr and restrained molecular dynamics: Comparison of biologically active Boc‐Trp‐(N‐Me)Nle‐Asp‐Phe‐NH2 and inactive Boc‐Trp‐(N‐Me)Phe‐Asp‐Phe‐NH2 , 1994, Biopolymers.

[21]  B. Roques,et al.  Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties. , 1993, Journal of medicinal chemistry.

[22]  P. Corringer,et al.  CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. , 1993, Journal of medicinal chemistry.

[23]  Hill,et al.  Rationally designed ‘dipeptoid’ analogues of cholecystokinin (CCK): C-terminal structure-activity relationships of α-methyl tryptophan derivatives , 1993 .

[24]  D. Fry,et al.  Analogs of CCK incorporating conformationally constrained replacements for Asp32. , 1992, Journal of medicinal chemistry.

[25]  A. Mcelroy,et al.  Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor. , 1992, Journal of medicinal chemistry.

[26]  M. Drysdale,et al.  Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. , 1992, Journal of medicinal chemistry.

[27]  C. Kneen,et al.  Rationally designed "dipeptoid" analogues of CCK. A Free-Wilson/Fujita-Ban analysis of some alpha-methyltryptophan derivatives as CCK-B antagonists. , 1992, Journal of medicinal chemistry.

[28]  M. Galas,et al.  Synthesis and biological activity of 2-phenylethyl ester analogues of C-terminal heptapeptide of cholecystokinin modified in Trp 30 region. , 2009, International journal of peptide and protein research.

[29]  T. Ott,et al.  CCK-8-related C-terminal tetrapeptides: affinities for central CCKB and peripheral CCKA receptors. , 1991, European journal of pharmacology.

[30]  D. Horwell.  Development of CCK-B antagonists , 1991, Neuropeptides.

[31]  J. Hunter,et al.  Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. , 1991, Journal of medicinal chemistry.

[32]  B. Bianchi,et al.  Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists. , 1990, Journal of medicinal chemistry.

[33]  B. Costall,et al.  Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Roques,et al.  Characterization of [3H] CCK4 binding sites in mouse and rat brain , 1988, Neuropeptides.

[35]  B. Roques,et al.  Enzyme-resistant CCK analogs with high affinities for central receptors , 1988, Peptides.

[36]  B. Roques,et al.  Cyclic cholecystokinin analogues with high selectivity for central receptors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Beeby,et al.  Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors. , 1987, Journal of medicinal chemistry.

[38]  T. Chase,et al.  Cholecystokinin octapeptide analogues stable to brain proteolysis , 1985, Peptides.

[39]  B. Roques,et al.  Synthesis and biological activity of Boc [Nle28, Nle31]CCK27–33, a highly potent CCK8 analogue , 1985, Peptides.

[40]  K. Inouye,et al.  Effects of caerulein-related peptides on cholecystokinin receptor bindings in brain and pancreas. , 1985, Biochemical pharmacology.

[41]  J. Bali,et al.  The role of the Asp-32 residue of cholecystokinin in gastric acid secretion and gastrin receptor recognition , 1983, Regulatory Peptides.

[42]  R. Jensen,et al.  The importance of the amino acid in position 32 of cholecystokinin in determining its interaction with cholecystokinin receptors on pancreatic acini. , 1981, Biochimica et biophysica acta.

[43]  S. Snyder,et al.  Distinct cholecystokinin receptors in brain and pancreas. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[44]  V. Mutt,et al.  Cholecystokinin (pancreozymin). 5. Hormonally active desamino derivative of Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2. , 1980, Journal of medicinal chemistry.

[45]  J. Rehfeld,et al.  Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the central nervous system and small intestine of man and hog. , 1978, The Journal of biological chemistry.

[46]  T. Satoh,et al.  [Reduction of organic compounds with sodium borohydride-transition metal salt systems. 3. Preparation of 2-aminomethyl-1,1-diphenyl-1-butene]. , 1970, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[47]  Gregory Ra,et al.  A NOTE ON THE NATURE OF THE GASTRIN-LIKE STIMULANT PRESENT IN ZOLLINGER-ELLISON TUMOURS. , 1964 .

[48]  R A GREGORY,et al.  The constitution and properties of two gastrins extracted from hog antral mucosa , 1964, Gut.